Press Releases

<<  Back

  View printer-friendly version

Aimmune Therapeutics to Participate in Three Investor Conferences in March

BRISBANE, Calif.--(BUSINESS WIRE)--Mar. 5, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management team will participate in three upcoming investor conferences in March:

Event:Cowen and Company 39th Annual Healthcare Conference
Date:Tuesday, March 12, 2019
Presentation Time:8:00 a.m. Eastern Time
Location:Boston, MA
Presenter: Jayson Dallas, M.D., President and Chief Executive Officer

Event:Barclays Global Healthcare Conference
Date:Wednesday, March 13, 2019
Presentation Time:2:05 p.m. Eastern Time
Location:Miami, FL
Presenter: Eric Bjerkholt, Chief Financial Officer, and Andrew Oxtoby, Chief Commercial Officer

Event: 31st Annual ROTH Conference
Date:Monday, March 18, 2019
Presentation Time:1:30 p.m. Pacific Time/4:30 p.m. Eastern Time
Location:Laguna Niguel, CA
Presenter: Eric Bjerkholt, Chief Financial Officer

Live webcasts of the presentations will be accessible on the Events page under the Investor Relations section of the Aimmune website at www.aimmune.com. Replays of the webcasts will be available following each webcast.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc., is a biopharmaceutical company developing oral treatments for life-threatening food allergies. The company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to provide meaningful levels of protection against allergic reactions resulting from accidental exposure to food allergens by desensitizing patients with defined, precise amounts of key allergens. Aimmune’s first investigational biologic product using CODIT™, AR101 for the treatment of peanut allergy, has received the FDA’s Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4-17 years of age. Aimmune’s regulatory filing for marketing approval of AR101 in the United States (submitted 4Q18) is based on data from the pivotal Phase 3 PALISADE clinical trial of AR101, which in 4-17 year-old subjects met its primary and key secondary endpoints, and additional ongoing and completed AR101 clinical trials. Aimmune expects to file for marketing approval of AR101 in Europe mid-2019. Aimmune has filed an IND application for its second product, AR201, for the treatment of egg allergy and intends to start a randomized Phase 2 clinical trial mid-2019. For more information, please see www.aimmune.com.

This press release concerns AR101, a product candidate that is under clinical investigation, and AR201, a product candidate that Aimmune expects will be under clinical investigation in 2019. Neither AR101 nor AR201 has been approved for marketing by the FDA or the European Medicines Agency (EMA). AR101 and AR201 are currently limited to investigational use, and no representation is made as to their safety or effectiveness for the purposes for which they are being investigated.

Source: Aimmune Therapeutics, Inc.

Investors
Laura Hansen, Ph.D., 650-396-3814
lhansen@aimmune.com

Media
Alison Marquiss, 650-376-5583
amarquiss@aimmune.com